Cystic Fibrosis Pulmonary Infection
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. Chronic pulmonary infections in CF patients, a significant portion which involves Pseudomonas aeruginosa, are characterized by persistence, biofilm formation, evasion of the host’s immune response, and resistance to multiple therapeutic agents. Multispecies biofilm formed by combinations of CF-relevant bacteria have demonstrated greater resistance, virulence and pathogenicity than comparable single-species biofilms. The presence of such complex biofilms in the lungs of CF patients are considered to be largely responsible for the chronic, persistent nature of these pulmonary infections, which are not only responsible for chronic, ongoing and progressive morbidity, but are also ultimately responsible for mortality in this population.
Chronic, CF-related pulmonary infections represent a major health care burden, being responsible for: significant loss of productivity; morbidity; reduced quality of life; and premature mortality frequently related to pulmonary infections.
Microbion’s compounds with their dual antimicrobial and anti-biofilm properties, represent a unique approach to treating resistant, chronic CF infections. This represents a critical area of immediate and advancing unmet medical need with CF patients.
Additionally, there are multiple lower respiratory tract infections and conditions with Pseudomonas spp., Staphylococcus spp., Streptococcus spp., Mycobacterium spp., or Haemophilus spp. infection (such as non-CF bronchiectasis, bronchitis, community- or ventilator-associated pneumonia, non-tuberculous mycobacterium infection, etc.), which may all benefit from an inhaled application of Microbion’s compounds.
Cystic Fibrosis Foundation. Cystic Fibrosis Foundation by the Numbers. July 1, 2017.